SGHT

SGHT

Sight Sciences Inc

Sight Sciences develops and sells surgical and nonsurgical devices for glaucoma and dry eye treatment. Its products include OMNI, SION, and TearCare systems, serving hospitals and eyecare professionals in the U.S. to improve patient outcomes.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$219today

Score Overview

1 Year
Score
Net Growth22.56%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth7.77%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score6.4
Net Growth52.74%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth70.31%
Rev Trend60%
Revenue Consistencyโ€”
All Time
Score
Net Growth52.74%
Net Trend80%
Net Income Consistency
Rev Growth70.31%
Rev Trend60%
Revenue Consistency

See the full market ranking โ†’

Sight Sciences Inc fundamental performance

Between 2021 and 2025, revenue grew from $ 48M to $ 77M and net income went from -$ 62M to -$ 38M. Revenue increased in 60% of the years measured; net income in 80%.

Sight Sciences Inc currently holds a 5-year HDB Score of 6.4 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 8.28โ€”
1 Year2025-08-12
$ 4.2594.82%
5 Years2021-08-12
$ 37.79-78.09%
All Time2021-07-15
$ 33.50-75.28%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 83M-$ 29M$ 79M
2025$ 77M-$ 38M$ 91M
2024$ 79M-$ 51M$ 120M
2023$ 81M-$ 55M$ 138M
2022$ 71M-$ 86M$ 185M
IPO2021$ 48M-$ 62M$ 260M

Explore beyond SGHT

You're looking at Sight Sciences Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies